Anti-CD3 monoclonal antibody treatment in newly diagnosed Type 1 diabetes patients: A hypothetical modelling analysis

Diabetic Medicine

Volumn 27, Issue 2, 2010, Pages 189-196

  Smith Palmer, J ^a   Curtis, B H ^b   Boye, K S ^b   Goodall, G ^a   Pillemer, S R ^c  

^a IQVIA   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c Analytical Sciences   (United States)

Author keywords

Anti CD3 monoclonal antibody; Economic model; Glycaemic control; Type 1 diabetes; cells

Indexed keywords

CD3 ANTIBODY; CHOLESTEROL; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; TRIACYLGLYCEROL; CD3 ANTIGEN;

ADULT; ALCOHOL CONSUMPTION; ANGINA PECTORIS; ARTICLE; BODY MASS; CATARACT; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; COMPUTER MODEL; COMPUTER SIMULATION; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE DURATION; DRUG EFFICACY; FEMALE; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPOTHESIS; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; KIDNEY DISEASE; KIDNEY FAILURE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PERIPHERAL VASCULAR DISEASE; PROTEINURIA; QUALITY OF LIFE; RETINA MACULA EDEMA; STROKE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; ULCER; VISUAL IMPAIRMENT; ADOLESCENT; BIOLOGICAL MODEL; COHORT ANALYSIS; DIABETES MELLITUS, TYPE 1; IMMUNOLOGY;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; COHORT STUDIES; COMPUTER SIMULATION; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; LIFE EXPECTANCY; MALE; MODELS, BIOLOGICAL; QUALITY OF LIFE;

EID: 76249096453     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2009.02902.x     Document Type: Article

References (21)

1. Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006 355 : 1318 1330.
2. Ryan EA, Lakey JR, Rajotte RV, Korbutt GS, Kin T, Imes S et al. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 2001 50 : 710 719.
3. Huurman VA, van der Meide PE, Duinkerken G, Willemen S, Cohen IR, Elias D et al. Immunological efficacy of heat shock protein 60 peptide DiaPep277 therapy in clinical type I diabetes. Clin Exp Immunol 2008 152 : 488 497.
4. Lazar L, Ofan R, Weintrob N, Avron A, Tamir M, Elias D et al. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study. Diabetes Metab Res Rev 2007 23 : 286 291.
5. Parish NM, Hutchings PR, Waldmann H, Cooke A. Tolerance to IDDM induced by CD4 antibodies in nonobese diabetic mice is reversed by cyclophosphamide. Diabetes 1993 42 : 1601 1605.
6. Hu CY, Rodriguez-Pinto D, Du W, Ahuja A, Henegariu O, Wong FS et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest 2007 117 : 3857 3867.
7. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002 346 : 1692 1698.
8. Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005 54 : 1763 1769.
9. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005 352 : 2598 2608. (Pubitemid 41007846)
10. Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 1997 158 : 2947 2954.
11. Palmer AJ, Roze S, Valentine W, Minshall M, Foos V, Lurati F et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004 20 (Suppl. 1 S27 S40.
12. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004 20 (Suppl. 1 5 26.
13. Liese AD, D'Agostino RB Jr., Hamman RF, Kilgo PD, Lawrence JM, Liu LL et al. The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics 2006 118 : 1510 1518.
14. Lloyd A, Swinburn P, Boye K, Curtis B, Sarpong E, Goldsmith K et al. A valuation of infusion therapy to preserve islet function in type 1 diabetes. Value in Health 2010 In press).
15. White NH, Sun W, Cleary PA, Danis RP, Davis MD, Hainsworth DP et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol 2008 126 : 1707 1715.
16. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005 353 : 2643 2653.
17. Nir T, Melton DA, Dor Y. Recovery from diabetes in mice by beta cell regeneration. J Clin Invest 2007 117 : 2553 2561.
18. Khalaileh A, Gonen-Gross T, Magenheim J, Nir T, Porat S, Salpeter S et al. Determinants of pancreatic beta-cell regeneration. Diabetes Obes Metab 2008 10 (Suppl. 4 128 135.
19. Sherry NA, Kushner JA, Glandt M, Kitamura T, Brillantes AM, Herold KC. Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes. Diabetes 2006 55 : 3238 3245.
20. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993 329 : 977 986.
21. Daneman D, Clarson C. Residual beta-cell function in children with type1 diabetes: measurement and impact on glycemic control. Clin Invest Med 1987 10 : 484 487.